These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34973165)

  • 1. Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers.
    Vanshylla K; Fan C; Wunsch M; Poopalasingam N; Meijers M; Kreer C; Kleipass F; Ruchnewitz D; Ercanoglu MS; Gruell H; Münn F; Pohl K; Janicki H; Nolden T; Bartl S; Stein SC; Augustin M; Dewald F; Gieselmann L; Schommers P; Schulz TF; Sander LE; Koch M; Łuksza M; Lässig M; Bjorkman PJ; Klein F
    Cell Host Microbe; 2022 Jan; 30(1):69-82.e10. PubMed ID: 34973165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
    Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
    mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
    Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape.
    Starr TN; Czudnochowski N; Liu Z; Zatta F; Park YJ; Addetia A; Pinto D; Beltramello M; Hernandez P; Greaney AJ; Marzi R; Glass WG; Zhang I; Dingens AS; Bowen JE; Tortorici MA; Walls AC; Wojcechowskyj JA; De Marco A; Rosen LE; Zhou J; Montiel-Ruiz M; Kaiser H; Dillen JR; Tucker H; Bassi J; Silacci-Fregni C; Housley MP; di Iulio J; Lombardo G; Agostini M; Sprugasci N; Culap K; Jaconi S; Meury M; Dellota E; Abdelnabi R; Foo SC; Cameroni E; Stumpf S; Croll TI; Nix JC; Havenar-Daughton C; Piccoli L; Benigni F; Neyts J; Telenti A; Lempp FA; Pizzuto MS; Chodera JD; Hebner CM; Virgin HW; Whelan SPJ; Veesler D; Corti D; Bloom JD; Snell G
    Nature; 2021 Sep; 597(7874):97-102. PubMed ID: 34261126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses.
    Wang P; Casner RG; Nair MS; Yu J; Guo Y; Wang M; Chan JF; Cerutti G; Iketani S; Liu L; Sheng Z; Chen Z; Yuen KY; Kwong PD; Huang Y; Shapiro L; Ho DD
    Emerg Microbes Infect; 2022 Dec; 11(1):147-157. PubMed ID: 34836485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants.
    Li T; Xue W; Zheng Q; Song S; Yang C; Xiong H; Zhang S; Hong M; Zhang Y; Yu H; Zhang Y; Sun H; Huang Y; Deng T; Chi X; Li J; Wang S; Zhou L; Chen T; Wang Y; Cheng T; Zhang T; Yuan Q; Zhao Q; Zhang J; McLellan JS; Zhou ZH; Zhang Z; Li S; Gu Y; Xia N
    Nat Commun; 2021 Sep; 12(1):5652. PubMed ID: 34580306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
    Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
    Front Immunol; 2021; 12():793953. PubMed ID: 34899762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition.
    Kramer KJ; Johnson NV; Shiakolas AR; Suryadevara N; Periasamy S; Raju N; Williams JK; Wrapp D; Zost SJ; Walker LM; Wall SC; Holt CM; Hsieh CL; Sutton RE; Paulo A; Nargi RS; Davidson E; Doranz BJ; Crowe JE; Bukreyev A; Carnahan RH; McLellan JS; Georgiev IS
    Cell Rep; 2021 Oct; 37(1):109784. PubMed ID: 34592170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.
    Cameroni E; Bowen JE; Rosen LE; Saliba C; Zepeda SK; Culap K; Pinto D; VanBlargan LA; De Marco A; di Iulio J; Zatta F; Kaiser H; Noack J; Farhat N; Czudnochowski N; Havenar-Daughton C; Sprouse KR; Dillen JR; Powell AE; Chen A; Maher C; Yin L; Sun D; Soriaga L; Bassi J; Silacci-Fregni C; Gustafsson C; Franko NM; Logue J; Iqbal NT; Mazzitelli I; Geffner J; Grifantini R; Chu H; Gori A; Riva A; Giannini O; Ceschi A; Ferrari P; Cippà PE; Franzetti-Pellanda A; Garzoni C; Halfmann PJ; Kawaoka Y; Hebner C; Purcell LA; Piccoli L; Pizzuto MS; Walls AC; Diamond MS; Telenti A; Virgin HW; Lanzavecchia A; Snell G; Veesler D; Corti D
    Nature; 2022 Feb; 602(7898):664-670. PubMed ID: 35016195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.
    Graham C; Seow J; Huettner I; Khan H; Kouphou N; Acors S; Winstone H; Pickering S; Galao RP; Dupont L; Lista MJ; Jimenez-Guardeño JM; Laing AG; Wu Y; Joseph M; Muir L; van Gils MJ; Ng WM; Duyvesteyn HME; Zhao Y; Bowden TA; Shankar-Hari M; Rosa A; Cherepanov P; McCoy LE; Hayday AC; Neil SJD; Malim MH; Doores KJ
    Immunity; 2021 Jun; 54(6):1276-1289.e6. PubMed ID: 33836142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance.
    Zou J; Li L; Zheng P; Liang W; Hu S; Zhou S; Wang Y; Zhao J; Yuan D; Liu L; Wu D; Xu M; Zhang F; Zhu M; Wu Z; Cao X; Ni M; Ling X; Wu Y; Kuang Z; Hu M; Li J; Li X; Guo X; Xu T; Jiang H; Gao C; Yu M; Liu J; Zhong N; Zhou J; Huang JA; Jin T; He J
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35108220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses.
    Banach BB; Cerutti G; Fahad AS; Shen CH; Oliveira De Souza M; Katsamba PS; Tsybovsky Y; Wang P; Nair MS; Huang Y; Francino-Urdániz IM; Steiner PJ; Gutiérrez-González M; Liu L; López Acevedo SN; Nazzari AF; Wolfe JR; Luo Y; Olia AS; Teng IT; Yu J; Zhou T; Reddem ER; Bimela J; Pan X; Madan B; Laflin AD; Nimrania R; Yuen KY; Whitehead TA; Ho DD; Kwong PD; Shapiro L; DeKosky BJ
    Cell Rep; 2021 Oct; 37(1):109771. PubMed ID: 34587480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies.
    Jette CA; Cohen AA; Gnanapragasam PNP; Muecksch F; Lee YE; Huey-Tubman KE; Schmidt F; Hatziioannou T; Bieniasz PD; Nussenzweig MC; West AP; Keeffe JR; Bjorkman PJ; Barnes CO
    Cell Rep; 2021 Sep; 36(13):109760. PubMed ID: 34534459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2.
    Xie J; Ding C; He J; Zhang Y; Ni S; Zhang X; Chen Q; Wang J; Huang L; He H; Li W; Ma H; Jin T; Zhang S; Gao Y
    Front Immunol; 2021; 12():715464. PubMed ID: 34539645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants.
    Shrestha LB; Tedla N; Bull RA
    Front Immunol; 2021; 12():752003. PubMed ID: 34646276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency.
    Mariotti S; Capocefalo A; Chiantore MV; Iacobino A; Teloni R; De Angelis ML; Gallinaro A; Pirillo MF; Borghi M; Canitano A; Michelini Z; Baggieri M; Marchi A; Bucci P; McKay PF; Acchioni C; Sandini S; Sgarbanti M; Tosini F; Di Virgilio A; Venturi G; Marino F; Esposito V; Di Bonito P; Magurano F; Cara A; Negri D; Nisini R
    Front Immunol; 2021; 12():750386. PubMed ID: 34764961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
    Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
    Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broad sarbecovirus neutralization by a human monoclonal antibody.
    Tortorici MA; Czudnochowski N; Starr TN; Marzi R; Walls AC; Zatta F; Bowen JE; Jaconi S; Di Iulio J; Wang Z; De Marco A; Zepeda SK; Pinto D; Liu Z; Beltramello M; Bartha I; Housley MP; Lempp FA; Rosen LE; Dellota E; Kaiser H; Montiel-Ruiz M; Zhou J; Addetia A; Guarino B; Culap K; Sprugasci N; Saliba C; Vetti E; Giacchetto-Sasselli I; Fregni CS; Abdelnabi R; Foo SC; Havenar-Daughton C; Schmid MA; Benigni F; Cameroni E; Neyts J; Telenti A; Virgin HW; Whelan SPJ; Snell G; Bloom JD; Corti D; Veesler D; Pizzuto MS
    Nature; 2021 Sep; 597(7874):103-108. PubMed ID: 34280951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.